These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28430820)

  • 1. Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study.
    Trotta F; Spila-Alegiani S; Da Cas R; Rajevic M; Conti V; Venegoni M; Rossi M; Traversa G
    PLoS One; 2017; 12(4):e0176276. PubMed ID: 28430820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study.
    Spila-Alegiani S; Trotta F; Da Cas R; Rossi M; Venegoni M; Traversa G
    COPD; 2018 Oct; 15(5):418-423. PubMed ID: 30822243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.
    Trotta F; Da Cas R; Rajevic M; Rossi M; Traversa G
    BMJ Open; 2015 May; 5(5):e006619. PubMed ID: 26009573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
    Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiotropium Respimat inhaler and the risk of death in COPD.
    Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
    N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
    Verhamme KM; Afonso A; Romio S; Stricker BC; Brusselle GG; Sturkenboom MC
    Eur Respir J; 2013 Sep; 42(3):606-15. PubMed ID: 23520322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
    Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
    van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
    Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
    Ichinose M; Fujimoto T; Fukuchi Y
    Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
    Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
    Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
    Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
    Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tiotropium Respimat(®) vs. HandiHaler(®): real-life usage and TIOSPIR trial generalizability.
    Schmiedl S; Fischer R; Ibanez L; Fortuny J; Thürmann P; Ballarin E; Ferrer P; Sabaté M; Rottenkolber D; Gerlach R; Tauscher M; Reynolds R; Hasford J; Rottenkolber M
    Br J Clin Pharmacol; 2016 Feb; 81(2):379-88. PubMed ID: 26506314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
    Tang Y; Massey D; Zhong NS
    Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.
    Hohlfeld JM; Furtwaengler A; Könen-Bergmann M; Wallenstein G; Walter B; Bateman ED
    Int J Clin Pract; 2015 Jan; 69(1):72-80. PubMed ID: 25496316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD.
    Verhamme KM; Afonso AS; van Noord C; Haag MD; Koudstaal PJ; Brusselle GG; Sturkenboom MC
    Pulm Pharmacol Ther; 2012 Feb; 25(1):19-26. PubMed ID: 22051450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiotropium formulations and safety: a network meta-analysis.
    Cazzola M; Calzetta L; Rogliani P; Matera MG
    Ther Adv Drug Saf; 2017 Jan; 8(1):17-30. PubMed ID: 28203364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.
    Tashkin DP; Leimer I; Metzdorf N; Decramer M
    Respir Res; 2015 Jun; 16(1):65. PubMed ID: 26031308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium Respimat Soft Mist Inhaler versus HandiHaler to improve sleeping oxygen saturation and sleep quality in COPD.
    Bouloukaki I; Tzanakis N; Mermigkis C; Giannadaki K; Moniaki V; Mauroudi E; Michelakis S; Schiza SE
    Sleep Breath; 2016 May; 20(2):605-12. PubMed ID: 26407963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
    Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
    PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.